Minnow Street Minnow Street
Buy Day today: Poor Neutral (49) Good Mixed market breadth · no major macro event

Clover Health Investments Corp (CLOV)

Healthcare Healthcare Plans
4.50 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock

Appears in These Scanners

This stock currently matches 16 of our scanner strategies — each hit links to the scanner.

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Basics

Market Cap
2.7Mrd. $
Shares Outstanding
431Mio.
Float
94.8%
Beta
2.4

Performance

Perf. 1M
27.00%
Perf. 3M
203.40%
Perf. 6M
109.90%
YTD Performance (%)
115.30%
52-Week-High Distance
-2.6%

Valuation

P/E
Forward P/E
82.0
PEG
P/B
P/S
1.2
EV/EBITDA
-0.6
Price/FCF
50.4

Profitability

Gross Margin
18.4%
EBIT Margin
3.7%
Net Margin
-2.6%
Return on Equity
-16.9%
Return on Assets
-5.6%

Balance Sheet & Safety

Equity Ratio
48.7%
Debt/Equity
warning zone
Altman Z
-5.82
Piotroski
6 von 9

Growth

Sales Growth Last Quarter
62.00%
EPS Growth Last Quarter
0.00%
Sales Growth (Year)
40.34%
Forward Sales Growth
14.19%
Forward EPS Growth
11.10%

Quality & Screener

Stage
2
Top 10%
RS Rating
95
EPS Rating
42
Piotroski
6 von 9
Fundamental Rating
C (-2 von 100)
warning zone
Altman Z
-5.82

AI Rating

Uses AI

Clover Health ist im Kern ein Medicare-Advantage-Versicherer (ein einziges berichtspflichtiges Segment: Insurance); die hauseigene KI-/Machine-Learning-Software „Clover Assistant" dient nachweislich dem operativen Kostenmanagement (Steuerung der Medizinkostenquote), ist aber keine belegte eigenständige Umsatzquelle. Die externe SaaS-Vermarktung als „Counterpart Assistant" wird in den Risikofaktoren ausdrücklich als noch nicht erfolgreicher „launch" beschrieben — daher „nutzt", nicht „verkauft".

View the full file — quotes, sources, reviewed filings
„Our proprietary software platform, Clover Assistant (licensed externally as Counterpart Assistant), supports clinical real-time decision making at the point of care by equipping the clinical with data and insights."

Unsere firmeneigene Softwareplattform Clover Assistant (extern lizenziert als Counterpart Assistant) unterstützt die klinische Echtzeit-Entscheidungsfindung am Behandlungsort, indem sie das klinische Personal mit Daten und Erkenntnissen ausstattet.

10-K · 2026-02-27 · View SEC filing
„...generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the most relevant, personalized information about each patient to his or her provider."

... erzeugt auf Behandler ausgerichtete Erkenntnisse aus maschinellem Lernen, künstlicher Intelligenz und Regelwerken und stößt Handlungen an, indem sie die relevantesten, personalisierten Informationen zu jedem Patienten an dessen Behandler ausspielt.

10-K · 2026-02-27 · View SEC filing
„Our launch of Counterpart Assistant as a Software-as-a-Service (“SaaS”) product for external payors and providers serving the Medicare eligible population may not be successful, and, as a result, our business may be adversely affected."

Unsere Markteinführung von Counterpart Assistant als Software-as-a-Service-Produkt („SaaS") für externe Kostenträger und Leistungserbringer, die die Medicare-berechtigte Bevölkerung versorgen, könnte scheitern, und infolgedessen könnte unser Geschäft beeinträchtigt werden.

10-K · 2026-02-27 · View SEC filing

Filings Reviewed: 10-K 2026-02-27 · 10-Q 2026-05-08 · 10-Q 2025-11-07 · 10-Q 2025-08-08 · 10-Q 2025-05-09 · 10-K 2025-03-03

Rated on July 10, 2026 · How the Rating Is Built

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Sales Per Quarter ($M)
2024: Q4 · 337.0 Mio. $ Q4 2025: Q1 · 462.3 Mio. $ Q1 2025: Q2 · 477.6 Mio. $ Q2 2025: Q3 · 496.6 Mio. $ Q3 2025: Q4 · 487.7 Mio. $ Q4 2026: Q1 · 749.2 Mio. $ Q1
Earnings Per Share Per Quarter ($)
2024: Q4 · -0.04 $ Q4 2025: Q1 · 0.00 $ Q1 2025: Q2 · -0.02 $ Q2 2025: Q3 · -0.05 $ Q3 2025: Q4 · -0.10 $ Q4 2026: Q1 · 0.05 $ Q1
Net Margin Per Quarter (%)
2024: Q4 · -6.6 % Q4 2025: Q1 · -0.3 % Q1 2025: Q2 · -2.2 % Q2 2025: Q3 · -4.9 % Q3 2025: Q4 · -10.1 % Q4 2026: Q1 · 3.6 % Q1
Operating Cash Flow Per Quarter ($M)
2024: Q4 · -85.8 Mio. $ Q4 2025: Q1 · -16.3 Mio. $ Q1 2025: Q2 · 5.4 Mio. $ Q2 2025: Q3 · 12.1 Mio. $ Q3 2025: Q4 · -68.2 Mio. $ Q4 2026: Q1 · 107.9 Mio. $ Q1
Free Cash Flow Per Quarter ($M)
2024: Q4 · -86.1 Mio. $ Q4 2025: Q1 · -16.5 Mio. $ Q1 2025: Q2 · 4.8 Mio. $ Q2 2025: Q3 · 11.4 Mio. $ Q3 2025: Q4 · -68.7 Mio. $ Q4 2026: Q1 · 107.0 Mio. $ Q1
Sales Growth vs. Year-Ago Quarter (%)
2024: Q4 · -34.0 % Q4 2025: Q1 · 33.3 % Q1 2025: Q2 · 34.1 % Q2 2025: Q3 · 50.1 % Q3 2025: Q4 · 44.7 % Q4 2026: Q1 · 62.0 % Q1
EPS Growth vs. Year-Ago Quarter (%)
2025: Q2 · -238.9 % Q2
Price Change in Quarter (%)
2024: Q4 · 11.7 % Q4 2025: Q1 · 14.0 % Q1 2025: Q2 · -22.3 % Q2 2025: Q3 · 9.7 % Q3 2025: Q4 · -23.2 % Q4 2026: Q1 · -25.1 % Q1

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.04 337 -34.00 -6.60 -86 -86
2025: Q1 0.00 462 33.30 -0.30 -16 -17
2025: Q2 -0.02 -238.90 478 34.10 -2.20 5 5
2025: Q3 -0.05 497 50.10 -4.90 12 11
2025: Q4 -0.10 488 44.70 -10.10 -68 -69
2026: Q1 0.05 749 62.00 3.60 108 107
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

Clover Health Investments, Corp. bietet Medicare-Advantage-Pläne in den USA an.

CEO Insider Trades (12 Mo.)selling own stock
Employees724
HeadquartersWilmington, DE
Websitecloverhealth.com
IPO Date2. Jan 2001
Next Earnings4. Aug 2026

Management

Management
Name Title Birth Year
Vivek Garipalli Co-Founder & Executive Chairman 1979
Andrew Toy Co-Founder, CEO & Director 1979
Brady Priest J.D. CEO of Clover Care Services 1976
Jamie L. Reynoso Chief Executive Officer of Medicare Advantage 1969
Conrad Wai CEO of Counterpart Health 1981
Clay Thornton Interim Chief Financial Officer 1990
Joseph Frank Oldakowski VP of Finance, Controller & Principal Accounting Officer 1983
Wendy Richey Chief Compliance Officer
Karen Soares Chief Legal Officer, General Counsel, Senior VP & Corporate Secretary 1978
Rachel Fish Chief People Officer

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?